Eli Lilly and Company, AbbVie, and D-Wave Quantum are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are equity shares of companies engaged in researching, developing, manufacturing and marketing medicinal drugs. They trade on public stock exchanges and their prices are driven by factors such as clinical trial results, regulatory approvals, patent lifecycles and shifts in healthcare demand. Investors often view them as a source of growth and dividends, but they also carry risks related to stringent regulations, patent expirations and potential litigation. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of NYSE:LLY traded up $19.73 during midday trading on Thursday, reaching $735.29. 3,266,761 shares of the company were exchanged, compared to its average volume of 3,572,640. The stock has a market cap of $696.86 billion, a PE ratio of 62.75, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The business's fifty day moving average is $801.10 and its two-hundred day moving average is $808.28. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53.
Read Our Latest Research Report on LLY
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of NYSE:ABBV traded up $2.45 on Thursday, reaching $179.89. The company's stock had a trading volume of 7,516,521 shares, compared to its average volume of 6,214,843. The company has a 50-day simple moving average of $192.59 and a 200 day simple moving average of $187.16. The company has a debt-to-equity ratio of 17.94, a quick ratio of 0.55 and a current ratio of 0.66. AbbVie has a 52-week low of $153.58 and a 52-week high of $218.66. The company has a market cap of $318.22 billion, a P/E ratio of 74.93, a PEG ratio of 1.62 and a beta of 0.56.
Read Our Latest Research Report on ABBV
D-Wave Quantum (QBTS)
D-Wave Quantum Inc. develops and delivers quantum computing systems, software, and services worldwide. The company offers Advantage, a fifth-generation quantum computer; Ocean, a suite of open-source python tools; and Leap, a cloud-based service that provides real-time access to a live quantum computer, as well as access to Advantage, hybrid solvers, the Ocean software development kit, live code, demos, learning resources, and a vibrant developer community.
NYSE:QBTS traded down $0.03 during mid-day trading on Thursday, hitting $11.06. 101,198,359 shares of the stock traded hands, compared to its average volume of 37,564,544. The firm's 50 day moving average is $7.73 and its two-hundred day moving average is $5.98. D-Wave Quantum has a 52 week low of $0.75 and a 52 week high of $12.46. The stock has a market capitalization of $3.22 billion, a price-to-earnings ratio of -26.09 and a beta of 0.90.
Read Our Latest Research Report on QBTS
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
